Walgreens Boots Alliance stock gains as new COVID-19 vaccines roll out

Walgreens Boots Alliance, Inc. (ISIN US9314271019) stock is trading modestly higher as of September 4, 2026, with investors watching both the companys pharmacy traffic from updated COVID-19 vaccines and the next set of earnings figures.

Vaccine rollout supports pharmacy traffic

According to a press release distributed via PR Newswire on September 4, 2026, Walgreens has begun offering 2026-2027 COVID-19 vaccines for eligible patients in its stores.

The release notes that the chain is combining COVID-19, flu, RSV, pneumococcal and other vaccines in single visits, a setup that tends to increase in-store traffic and prescription activity during the fall and winter season.

Stock performance and market context

On September 4, 2026, a London-listed Walgreens Boots Alliance instrument with the ticker 0LSZ.IL was quoted at 11.33 British pounds, up 0.18 pounds or 1.65 percent on the day, according to market data compiled by Yahoo Finance.

This move comes in a generally supportive US equity environment, with major indices closing higher as rate hike concerns eased, as reported by a US market overview in The Business Times.

Pharmacy and retail focus

Walgreens Boots Alliance derives a substantial portion of its revenue from pharmacy services, including vaccinations and prescription dispensing, alongside front-of-store retail sales such as over-the-counter medicines and health products.

The introduction of updated 2026-2027 COVID-19 vaccines, combined with other immunizations in one visit, strengthens Walgreens proposition as a one-stop health destination for US consumers as the respiratory virus season approaches.

Stock price snapshot and investor view

As of September 4, 2026, investors are watching Walgreens Boots Alliance stock for signs that higher vaccine and pharmacy activity can translate into steadier earnings and potentially improve sentiment toward the shares over the coming quarters.